Clinical trial
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in…
NCT00004584 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00004584 |
|---|---|
| Title | Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment |
| Official title | Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination Regimen(s) as Compared to a Reference Combination Regimen(s) in Antiretroviral-Experienced HIV-Infected Subjects |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanavir, Ritonavir, Saquinavir |
| Start date | Dec 1, 1999 |
| Primary completion | Jan 1, 2002 |
| Completion | Jan 1, 2002 |
| First posted | Aug 31, 2001 |
| Last update posted | May 4, 2011 |
| Countries | Canada, France, Germany, Italy, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: